Taking too much compounded tirzepatide causes severe nausea, vomiting, diarrhea, and abdominal pain that typically begin within a few hours and can last several days. Most cases are managed at home with fluids, anti-nausea medication, and time. A small number have required emergency-room or intensive-care admission for severe dehydration or pancreatitis.
If you suspect you took too much, call Poison Control at 1-800-222-1222 (free, 24/7). Go to the nearest emergency room or call 911 if symptoms are severe.
“Too much” means anything outside your prescribed weekly dose that delivers significantly more medication than your body is calibrated for. According to the prescribing information for the FDA-approved branded version of tirzepatide, the standard schedule starts at 2.5 mg once weekly, increases by 2.5 mg every four weeks under clinical supervision, and tops out at a maintenance dose of 5, 10, or 15 mg weekly. The prescribing information advises that doses should be spaced at least 72 hours apart, based on missed-dose guidance.
The most common scenarios that count as “too much”:
A single missed week followed by a return to the normal weekly dose is not an overdose. According to the prescribing information for the FDA-approved branded version of tirzepatide, if a dose is missed and the next scheduled dose is more than four days away, you can take the missed dose; if less than four days away, skip the missed dose and resume the regular schedule. A licensed clinician should advise on missed-dose handling.
If you suspect you injected more than your prescribed dose, your first call is Poison Control at 1-800-222-1222. The call is free, confidential, and available 24/7 in every U.S. state. The pharmacists and toxicologists who answer the line can tell you whether your specific situation needs home observation or medical care.
After Poison Control, message the Sunlight care team through the patient portal or call 1-877-378-7008. The care team will document the incident, and a licensed clinician will confirm when you should take your next dose. The care team is not a substitute for emergency triage; for an active overdose, call Poison Control first.
Have your vial nearby when you call. You will be asked the medication name, the concentration printed on the vial label, your prescribed dose, the time of injection, and an estimate of how much you actually took.
While you wait for guidance:
Seek immediate medical attention or call 911 if you have severe vomiting that will not stop, severe abdominal pain (especially pain that radiates to your back), signs of severe dehydration (no urination for 8 or more hours, severe dizziness, fainting), confusion, slurred speech, loss of consciousness, difficulty breathing, swelling of the face or throat, widespread hives, severe weakness, fast heartbeat, chest pain, or a seizure.
For a step-by-step incident-response guide, see I injected too much. What do I do
The pattern of an overdose is the same set of side effects patients see at therapeutic doses, except more severe, faster in onset, and longer-lasting. The reason is mechanism: tirzepatide is a dual GIP and GLP-1 receptor agonist that slows gastric emptying and reduces appetite, and a higher dose pushes those effects into pathological territory.
Within the first 24 hours after an over-injection, expect some combination of:
Symptoms typically peak in the first 24 to 72 hours and gradually improve over the following several days. According to the prescribing information for the FDA-approved branded version of tirzepatide, the elimination half-life is approximately five days, so the medication is still active in the body for several weeks after an overdose (roughly 25 days for near-complete elimination based on five half-lives), even as acute symptoms taper.
Most over-injections do not progress beyond severe nausea and dehydration. A small fraction do. Published case reports describe severe tirzepatide overdoses requiring intensive medical care, though these appear to be rare. The complications worth knowing about:
Vomiting and diarrhea cause fluid and electrolyte loss. According to the National Institutes of Health, severe dehydration can reduce blood flow to the kidneys and cause acute kidney injury, which is reversible if treated quickly but can become permanent if ignored. Signs to watch for: very dark urine, no urination for 8+ hours, dizziness on standing, dry mouth and lips, sunken eyes.
Inflammation of the pancreas. According to the prescribing information for the FDA-approved branded version of tirzepatide, pancreatitis has been observed in clinical trials of the medication at therapeutic doses. The risk at supratherapeutic doses is not well defined but may be increased. Signs: severe upper-abdominal pain that radiates to the back, persistent vomiting, fever, rapid heartbeat. Pancreatitis is a medical emergency. Go to the ER if you suspect it.
Tirzepatide alone rarely causes hypoglycemia in patients without diabetes. The risk is meaningful for patients who also take insulin or a sulfonylurea. According to the Mayo Clinic, the combination can drop blood sugar fast. Signs: shakiness, sweating, confusion, blurred vision, fast heartbeat, and in severe cases loss of consciousness or seizure.
Tirzepatide already slows gastric emptying as part of its therapeutic effect. At high doses, delayed gastric emptying may become more pronounced and prolonged, which can resemble gastroparesis-like symptoms.
Rare but possible. Signs of a severe allergic reaction (anaphylaxis): widespread hives, swelling of the face or throat, difficulty breathing, fast heartbeat. Call 911 immediately.
The U.S. Food and Drug Administration has issued specific alerts about dosing errors associated with compounded GLP-1 medications. The agency identified several patterns:
These patterns are concentrated in compounded medications because the prescription, the concentration, and the syringe vary by patient and by pharmacy, where the FDA-approved branded version of tirzepatide ships in a pre-filled pen with a fixed dose.
Sunlight ships compounded tirzepatide in a multi-dose vial with a dose card and instructions for the specific syringe in your kit. The kit is built to prevent these errors, but only if you follow the dose card.
The single most important step is to read your dose card every week before you draw. The card translates your prescribed milligram dose into the unit count for your specific vial concentration. Beyond that:
The full step-by-step is at How much medication do I draw?
If anything about your prescription, vial, or syringe looks different from your last shipment, message the Sunlight care team before you inject. The care team can confirm whether something has actually changed or whether the appearance is normal between batches.
Sunlight’s compounded tirzepatide is prepared by a licensed compounding pharmacy and is not FDA-approved. This article is educational and does not constitute medical advice; in a suspected overdose, your first call should be to Poison Control (1-800-222-1222), the Sunlight care team, or 911 depending on severity. A licensed clinician determines your specific dose and schedule. Individual results may vary.
Questions about your specific dose? Message the Sunlight care team through the patient portal.